Search results
What’s Happening With The Y Chromosome?
IFLScience· 2 days agoThe human Y chromosome isn’t what it used to be – long gone are the days when it used to be the same size as its pal, X. It’s now much smaller, but is it...
Black, white and shades of grey – what’s behind sprint’s race divide?
BBC via Yahoo Sports· 3 days agoFor Pitsiladis, genetic heritage is specific and shorter term. “The reality is that it's the genes...
Mixed public opinion on polygenic embryo screening for IVF
Science Daily· 3 days ago"This survey rings the alarm that geneticists, behavioral scientists, bioethicists, clinicians, and genetic counselors need to work together to figure out ways to communicate ...
Gene thought to raise risk for Alzheimer's may cause it
Dothan Eagle· 7 days agoFor the first time, researchers have identified a genetic form of late-in-life Alzheimer's disease —...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306
Gene thought to raise risk for Alzheimer’s may cause some cases
Temple Daily Telegram· 3 days agoFor the first time, researchers have identified a genetic form of late-in-life Alzheimer’s disease —...
Unlocking the body’s defences: understanding immunotherapy
The Conversation· 19 hours agoIn the battle against diseases, the human body boasts an intricate defence network capable of identifying and neutralising threats – the immune system. It serves as a guardian, constantly patrolling ...
Deciphering the Unusual Pattern of Bird Flu Symptoms in Cows
The Scientist· 2 days agoIn March 2024, the USDA confirmed that dairy cattle in Texas and Kansas had become infected with a...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger - Reneo Pharmaceuticals (NASDAQ:RPHM)
Benzinga· 4 days agoThe combined company will focus on advancing OnKure's pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program ...
